[go: up one dir, main page]

WO2021234554A3 - Novel composition for the treatment of viral infections - Google Patents

Novel composition for the treatment of viral infections Download PDF

Info

Publication number
WO2021234554A3
WO2021234554A3 PCT/IB2021/054246 IB2021054246W WO2021234554A3 WO 2021234554 A3 WO2021234554 A3 WO 2021234554A3 IB 2021054246 W IB2021054246 W IB 2021054246W WO 2021234554 A3 WO2021234554 A3 WO 2021234554A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
agent
adjuvant
primary active
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/054246
Other languages
French (fr)
Other versions
WO2021234554A2 (en
Inventor
Chandanmal pukhraj BOTHRA
Hemanth Kumar BOTHRA
Elayaraja NATARAJAN
Chitra AJITHAN VARMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nokha Trading LLP
Lyrus Life Sciences Pvt Ltd
Original Assignee
Nokha Trading LLP
Lyrus Life Sciences Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nokha Trading LLP, Lyrus Life Sciences Pvt Ltd filed Critical Nokha Trading LLP
Priority to CA3176914A priority Critical patent/CA3176914A1/en
Priority to AU2021276914A priority patent/AU2021276914A1/en
Publication of WO2021234554A2 publication Critical patent/WO2021234554A2/en
Publication of WO2021234554A3 publication Critical patent/WO2021234554A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to the combination of primary active agent and a mucolytic agent as an adjuvant for the treatment of Viral infections. The present invention relates to the combination of primary active agent and a mucolytic agent as an adjuvant specifically for the treatment of COVID-19. The present invention relates to the co-pack of primary active agent and a mucolytic agent as an adjuvant specifically for the treatment of COVID-19. The present invention specifically relates to composition comprising combination of anti-viral agent as primary active agent and a mucolytic agent as an adjuvant for the treatment of COVID-19. The present invention specifically relates composition comprising combination of anti-gout agent as primary active agent and a mucolytic agent as an adjuvant for the treatment of COVID-19. The present invention more specifically relates to the composition comprising Favipiravir as primary active agent and Carbocisteine as adjuvant, Colchicine as primary active agent and Carbocisteine as adjuvant for the treatment of COVID-19.
PCT/IB2021/054246 2020-05-20 2021-05-18 Novel composition for the treatment of viral infections Ceased WO2021234554A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3176914A CA3176914A1 (en) 2020-05-20 2021-05-18 Novel composition for the treatment of viral infections
AU2021276914A AU2021276914A1 (en) 2020-05-20 2021-05-18 Novel composition for the treatment of viral infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ININ202041021211 2020-05-20
IN202041021211 2020-05-20

Publications (2)

Publication Number Publication Date
WO2021234554A2 WO2021234554A2 (en) 2021-11-25
WO2021234554A3 true WO2021234554A3 (en) 2022-01-06

Family

ID=78709102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/054246 Ceased WO2021234554A2 (en) 2020-05-20 2021-05-18 Novel composition for the treatment of viral infections

Country Status (3)

Country Link
AU (1) AU2021276914A1 (en)
CA (1) CA3176914A1 (en)
WO (1) WO2021234554A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126169A1 (en) * 2021-12-31 2023-07-06 Unilever Ip Holdings B.V. Use of carboxymethyl cysteine compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309420A (en) * 2015-07-06 2017-01-11 广州白云山医药集团股份有限公司白云山制药总厂 Novel application of carbocisteine
WO2017049060A1 (en) * 2015-09-16 2017-03-23 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106309420A (en) * 2015-07-06 2017-01-11 广州白云山医药集团股份有限公司白云山制药总厂 Novel application of carbocisteine
WO2017049060A1 (en) * 2015-09-16 2017-03-23 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections

Also Published As

Publication number Publication date
AU2021276914A1 (en) 2022-12-01
CA3176914A1 (en) 2021-11-25
WO2021234554A2 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
WO2020198403A3 (en) Compositions comprising modified circular polyribonucleotides and uses thereof
AR112271A1 (en) COMPOSITIONS INCLUDING AN INHIBITOR OF RNA POLYMERASE AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
MX2023005160A (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma.
EP4360651A3 (en) Glp-1 compositions and uses thereof
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
MX2019009212A (en) Atazanavir (atv) analogues for treating hiv infections.
CL2021003208A1 (en) Prevention of highly pathogenic virus infections by topical application of povidone-iodine on mucous membranes
WO2020171727A3 (en) Mucoadhesive compositions and uses thereof
MX2025003398A (en) Novel tetraheterocycle compound
BR112022001912A2 (en) Cellular compositions comprising viral vectors and treatment methods
ZA202204941B (en) Cd73 inhibitors
MX2020003473A (en) Novel mek-inhibitor for the treatment of viral and bacterial infections.
CL2021001753A1 (en) Compounds derived from 2,4-diaminoquinazoline; pharmaceutical composition; and its use for the treatment of a viral infection, cancer, among others (divisional application 202002253).
MX2023007699A (en) Solid forms of a cdk2 inhibitor.
BR112022001365A2 (en) Crystalline forms of a cd73 inhibitor
MX2024010625A (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof.
MX2022010542A (en) Compositions and methods for reducing cytokine expression.
WO2021234554A3 (en) Novel composition for the treatment of viral infections
WO2020091583A3 (en) Cosmetics composition containing anti-oxidant
PH12022553548A1 (en) Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
BR112022023318A2 (en) MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X-ASSOCIATED DISORDERS
MX2022000232A (en) COMPOSITIONS AND METHODS TO TREAT OR AVOID EYE INFECTIONS WITH FILOCICLOVIR.
WO2021226037A8 (en) Treatment of viral infections
MX2021013613A (en) Active compound combination.
MX2021006654A (en) Use of cocculus hirsutus extract for treating dengue.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3176914

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021276914

Country of ref document: AU

Date of ref document: 20210518

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21808388

Country of ref document: EP

Kind code of ref document: A2